## LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims

1. **(Withdrawn)** A method for enhancing the development of a cellular immune response to a preselected antigen in a mammal comprising exposing ex vivo or in vivo dendritic cells from said mammal to a conjugate comprising said preselected antigen covalently bound to an antibody to DEC-205, and promoting maturation of said dendritic cells ex vivo or in vivo by CD40 ligation.

2. **(Withdrawn)** The method of claim 1 wherein said preselected antigen is a peptide antigen or a protein antigen.

3. **(Withdrawn)** The method of claim 3 wherein said peptide antigen or protein antigen is conjugated to said antibody to DEC-205 by means of a cross linking-agent.

4. **(Withdrawn)** The method of claim 2 wherein a light chain or a heavy chain of said antibody to DEC-205, and said peptide antigen or protein antigen, are present on a single polypeptide chain.

5. **(Withdrawn)** The method of claim 1 wherein said CD40 ligation is achieved by exposing said dendritic cell to an agonistic anti-CD40 antibody.

6. **(Previously Presented)** A method for enhancing the development of tolerance to a preselected antigen for which tolerance is desired, in a mammal comprising exposing ex vivo or in vivo dendritic cells from said mammal to a conjugate comprising said preselected antigen covalently bound to an anti-human DEC-205 antibody or an anti-murine DEC-205 antibody that binds to human DEC-205 under conditions that promote dendritic cell quiescence, said human

DEC-205 protein comprising an amino acid sequence as set forth in SEQ ID NO: 7, and wherein said preselected antigen is selected from the group consisting of allergens, autoantigens and antigens participating in allograft rejection.

7. **(Original)** The method of claim 6 wherein said preselected antigen is a peptide antigen or a protein antigen.

8. **(Original)** The method of claim 7 wherein said peptide or protein is conjugated to said antibody to DEC-205 by means of a cross-linking agent.

9. **(Original)** The method of claim 7 wherein a light chain or a heavy chain of said antibody to DEC-205, and said peptide antigen or protein antigen, are present on a single polypeptide chain.

10. **(Withdrawn)** A conjugate for enhanced delivery of a preselected protein or peptide antigen to a dendritic cell, said conjugate comprising said preselected protein or peptide antigen covalently bound to an antibody to DEC-205.

11. **(Withdrawn)** The conjugate of claim 10 wherein a light chain or a heavy chain of said antibody to DEC-205, and said peptide antigen or protein antigen, are present on a single polypeptide chain.

12. **(Withdrawn)** A method for enhancing the delivery of a preselected molecule into a dendritic cell comprising the steps of preparing a conjugate comprising said preselected molecule and an antibody to DEC-205, and exposing said conjugate to a dendritic cells, wherein said conjugate is delivered into said dendritic cell.

13. **(Previously Presented)** A method for enhancing the development of tolerance to a preselected antigen for which tolerance is desired in a mammal, comprising exposing ex vivo or in vivo dendritic cells from said mammal to a conjugate comprising said preselected antigen covalently bound to an anti-human DEC-205 antibody, wherein the antibody is reactive with an amino acid sequence as set forth in SEQ ID NO: 7, under conditions that promote dendritic cell

quiescence, wherein said preselected antigen is selected from the group consisting of allergens, autoantigens and antigens participating in allograft rejection.

14. **(Previously Presented)** A method for enhancing the development of tolerance to a preselected antigen for which tolerance is desired, in a mammal comprising exposing ex vivo or in vivo dendritic cells from said mammal to a conjugate comprising said preselected antigen covalently bound to an anti-murine DEC-205 antibody, wherein the antibody is reactive with an amino acid sequence as set forth in SEQ ID NO: 7, under conditions that promote dendritic cell quiescence, and wherein said preselected antigen is selected from the group consisting of allergens, autoantigens and antigens participating in allograft rejection.

15. **(Previously Presented)** The method of either one of claims 13 or 14, wherein said preselected antigen is a peptide antigen or a protein antigen.

16. **(Previously Presented)** The method of either one of claims 13 or 14, wherein said peptide or protein antigen is conjugated to said antibody to DEC-205 by means of a cross-linking agent.

17. **(Previously Presented)** The method of either one of claims 13 or 14, wherein a light chain or a heavy chain of said antibody to DEC-205, and said peptide antigen or protein antigen, are present on a single polypeptide chain.

18. **(Previously Presented)** A method for enhancing the development of tolerance to a preselected antigen in a mammal, the method comprising exposing ex vivo or in vivo dendritic cells from the mammal to a conjugate comprising the preselected antigen bound to an anti-mouse DEC-205 antibody that cross reacts with human DEC-205 under conditions that promote dendritic cell quiescence, wherein the mouse DEC-205 protein comprises the amino acid sequence of SEQ ID NO: 10.

19. **(Previously Presented)** The method of claim 18, wherein the preselected antigen is selected from the group consisting of allergens, autoantigens and antigens participating in allograft rejection.

20. **(Previously Presented)** The method of claim 19, wherein the preselected antigen is bound to the antibody to DEC-205 by means of a cross-linking agent.

21. **(Previously Presented)** The method of claim 18, wherein a light chain or a heavy chain of the antibody to DEC-205, and the preselected antigen, are present on a single polypeptide chain.